Please login to the form below

Not currently logged in
Email:
Password:

First application for FDA/EMA review pilot

Pfizer has submitted the first application for the European Medicines Agency's and the US Food and Drug Administration's 'quality by design' pilot for increased co-operation in drug evaluations

Pfizer has submitted the first application for the European Medicines Agency's (EMA) and the US Food and Drug Administration's (FDA) 'quality by design' pilot for increased co-operation in drug evaluations.

The voluntary pilot programme was announced in March 2011 to help ensure consistent implementation of certain guidelines from regulatory agencies when reviewing marketing applications for new drugs.

The programme is designed to encourage regular communication and consultation between the EMA and FDA during the assessment of the design and development of formulations and manufacturing processes listed in the application. This is to help ensure product manufacturing quality.

The pilot is being operated under the EMA's confidentiality arrangements with the FDA, covering issues related to medicinal products for human and veterinary use. In September 2010, the agencies said they would indefinitely extend these arrangements.

20th June 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...